News of the WeekBiomedical Ethics

Penn Report, Agency Heads Home In on Clinical Research

+ See all authors and affiliations

Science  02 Jun 2000:
Vol. 288, Issue 5471, pp. 1558-1559
DOI: 10.1126/science.288.5471.1558

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


This article has a correction. Please see:

Summary

Last week, clinical researchers began to find out what the consequences of the death of a teenager last fall in a gene therapy experiment at the University of Pennsylvania would be for Penn--and for national policy. Several federal agencies put forward proposals for sharply increasing the surveillance of human trials, especially those involving the use of viral carriers in gene therapy. And Penn, which has been in the hot seat for several investigations, announced a more rigorous system for approving and monitoring the use of human subjects that could add significantly to the cost of some types of academic research.

Related Content